Leerink Initiates Coverage on Absci Corporation, Citing Strong AI-Native Drug Development Pipeline

Leerink has recently commenced its coverage of Absci Corporation, assigning an "Outperform" rating and setting a price target of $12. This positive outlook is largely attributed to Absci's pioneering application of artificial intelligence in drug development. The firm specifically noted the promising progress of ABS-201, Absci's primary drug candidate, which is currently undergoing Phase 1/2 trials for the treatment of androgenetic alopecia. This AI-driven approach is expected to significantly enhance the efficiency and success rates in identifying and developing therapeutic proteins.

Looking ahead, Absci's CEO, Sean McClain, has indicated that the upcoming year, 2026, will be marked by a wealth of new data from their clinical programs. Among these, ABS-201, a long-acting anti-PRLR antibody, is particularly highlighted for its potential to introduce a novel treatment mechanism for alopecia, featuring less frequent dosing. The corporation has already successfully completed dosing across four single ascending dose cohorts, reporting encouraging safety and pharmacokinetic profiles, and has now advanced to multiple ascending dose cohorts. Furthermore, Absci has unveiled ABS-202, a preclinical anti-PRLR initiative, and established an advisory board for endometriosis research, engaging prominent experts from leading institutions such as Yale, Duke, UCSF, and the Mayo Clinic, signaling a strategic expansion of its therapeutic focus.

Absci Corporation's innovative strategy, combining deep learning AI with synthetic biology, positions it at the forefront of expanding the therapeutic capabilities of proteins. This blend of cutting-edge technology and a robust pipeline, as recognized by Leerink's coverage initiation, underscores the company's potential for significant advancements in the biotechnology sector. Absci's commitment to leveraging AI to tackle complex medical challenges offers a promising future for patients and stakeholders alike, striving for breakthroughs that can redefine treatment paradigms across various conditions.